metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology Detecting the risk for fatty liver, MASH, and insulin resistance using different...
Journal Information
Vol. 29. Issue S2.
Abstracts Asociación Mexicana del Hígado (AMH) 2023
(February 2024)
Share
Share
Download PDF
More article options
Vol. 29. Issue S2.
Abstracts Asociación Mexicana del Hígado (AMH) 2023
(February 2024)
Full text access
Detecting the risk for fatty liver, MASH, and insulin resistance using different indexes and markers of liver damage in young adults from West Mexico
Visits
254
Leonardo Leal-Mercado1,2, Arturo Panduro1,2, Saúl Laguna-Meraz1,2, Sonia Román1,2
1 Department of Genomic Medicine in Hepatology, Civil Hospital of Guadalajara "Fray Antonio Alcalde", Guadalajara, Jalisco, Mexico
2 Health Sciences Center, University of Guadalajara, Guadalajara, Jalisco, Mexico
This item has received
Article information
Abstract
Full Text
Download PDF
Statistics
Special issue
This article is part of special issue:
Vol. 29. Issue S2

Abstracts Asociación Mexicana del Hígado (AMH) 2023

More info
Introduction and Objectives

Previous studies conducted by our research group have demonstrated a high frequency of fatty liver and metabolic-associated steatohepatitis (MASH) in young Mexican population. Therefore, early detection of risk factors and metabolic abnormalities is important to prevent or reverse the progression to MASH. The objective of this study is to use non-invasive markers for the detection of insulin resistance (IR), the risk of fatty liver disease (FLD), liver damage, and metabolic-associated steatohepatitis (MASH) in young adult population from West Mexico

Materials and Patients

A cross-sectional study assessing the presence of IR using HOMA-IR and non-invasive assessment of the risk of fatty liver disease (FLD) (FLI ≥ 60), liver damage (HCG markers 19.6% to 58.8%), and metabolic associated steatohepatitis (MASH) (FIB-4: 1.45-3.25; APRI: ≥0.7-1.0; NAFLD Fibrosis Score: > 0.675) in young adults aged 18 to 45 years. Written informed consent was obtained from all participants. The Institutional Review Board approved this study.

Results

Fifty-three participants (37 women and 16 men) with an average age of 29.53 ± 8.33 years were recruited. A 80.7% had overweight and obesity (class I, II, III), with an average waist-to-height ratio of 0.55 ± 0.09. Additionally, 80.8% of the participants had one or more metabolic abnormalities; hypercholesterolemia (25%), hypertriglyceridemia (39.2%), hypoalphalipoproteinemia (64%), and IR (54.3%). A risk of 39.6% for NAFLD (FLI), 42.95% for liver damage (HCG markers), and 2% - 4% for MASH with intermediate hepatic fibrosis (F2-F3) and significant according to the FIB-4, APRI, and NAFLD Fibrosis Score markers, respectively, were identified.

Conclusions

A high prevalence of metabolic disorders and IR was detected, which may be related to a high risk of developing fatty liver disease (39.6%) and liver damage (42.95%), as well as MASH (2-4%) in the young Mexican adult population, suggesting the need of early prevention strategies.

Full Text

Ethical statement

The protocol was registered and approved by the Ethics Committee. The identity of the patients is protected. Consentment was obtained.

Declaration of interests

None

Funding

University of Guadalajara-Programa de Fortalecimiento de Institutos, Centros y Laboratorios.

Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos